Abstract Library

#3918 Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

Introduction: Gemcitabine, metronomic capecitabine and mitotane (M) combination (GemCap + M) is the most investigated and widely used regimen in 2nd and subsequent lines therapy of advanced adrenocortical cancer (ACC). In the largest retrospective study (N=145) only 28% of patients (pts) reached therapeutic concentration of mitotane (M), which translated into a significant improvement in the median progression free survival (PFS).

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Evdokimova E, Khoroshilov M,

Keywords: adrenocortical cancer, gemcitabine, capecitabine, GemCap, mitotane,

#3916 Temozolomide as second and subsequent lines of treatment in metastatic adrenocortical cancer: Prospective phase II clinical trial

Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. There are still no effective options for 2nd and subsequent lines of chemotherapy (ChT). Despite promising results of retrospective study with temozolomide (Tem), no prospective studies evaluating Tem efficacy have been published yet.

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Khoroshilov M, Gabrava M,

Keywords: adrenocortical cancer, temozolomide, mitotane,

#3573 Treatment of advanced adrenocortical cancer (ACC): Data from 152 patients of the national and multicenter ICARO_GETHI/SEEN registry

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis in stage IV with only one treatment regimen of chemotherapy (CT), etoposide, doxorubicin, and cisplatin (EDP) and mitotane with proven activity in a phase 3 trial.

Conference:

Presenting Author:

Authors: Álvarez-Escolá C, Ballester I, Garcia Donas J, Paja M, Iglesias C,

Keywords: Adrenocortical cancer, mitotane, chemotherapy, survival, registry,

#3562 Prognostic factors in stage I-III adrenocortical cancer (ACC): Data of 230 patients from the ICARO_GETHI/SEEN registry

Introduction: The scientific evidence on adjuvant treatment of adrenocortical carcinoma (ACC) is scarce and based on a retrospective Italian-German series.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Ballester I, Álvarez-Escolá C, Valdes N, Hernando J, Picon M,

Keywords: Adrenocortical cancer, Adjuvant treatment, Mitotane, Prognosis, Survival,

#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,